Generic
Solifenacin Succinate
16 brands available in the market
At a glance
Solifenacin Succinate is a muscarinic receptor antagonist used for the treatment of overactive bladder (OAB) symptoms such as frequent urination, urgent need to urinate, and inability to control urination.
Description
Solifenacin is a competitive muscarinic receptor antagonist. The bladder contains 80% M2 and 20% M3 receptors. Solifenacin's M3 receptor antagonism prevents detrusor muscle contraction, while M2 antagonism prevents smooth muscle contraction. It increases bladder capacity and reduces the urgency to urinate.
Indications
- Overactive bladder (OAB) – urgency, increased urinary frequency, urge incontinence
Therapeutic class
Anticholinergic / Antispasmodic
Pharmacological class
Muscarinic Receptor Antagonist
Pharmacology
Solifenacin blocks M2 and M3 muscarinic receptors in the bladder, relaxing the detrusor muscle, increasing bladder capacity, and reducing urinary urgency and frequency.
Mechanism of action
Relaxes the detrusor muscle by blocking muscarinic receptors in the bladder.
Dosage
Adult Dose (Oral):
- Starting: 5 mg once daily
- If needed and tolerated: 10 mg once daily
- With CYP3A4 inhibitors (ketoconazole, ritonavir): Max 5 mg/day
- Severe renal impairment (CrCl <30): Max 5 mg/day
- Moderate hepatic impairment (Child-Pugh B): Max 5 mg/day
Administration
- Take orally with or without food
- Swallow tablet whole; do not chew, crush, or break
- Take at the same time each day
Missed dose
If you miss a dose, take it as soon as you remember; if almost time for the next dose, skip it; do not double the dose.
Side effects
Common Side Effects:
- Dry mouth (very common: 11-22%)
- Constipation, nausea, dyspepsia
- Abdominal pain, blurred vision
- Urinary tract infection
Precautions & warnings
- Do not use in uncontrolled narrow-angle glaucoma, urinary retention, gastric retention
- Caution in clinically significant bladder outflow obstruction, GI obstructive disorders
- Severe renal or moderate hepatic impairment: Do not exceed 5 mg
- May affect driving ability (blurred vision, drowsiness)
Contraindications
- Hypersensitivity to solifenacin or any excipient
- Myasthenia gravis
- Urinary retention
- Uncontrolled narrow-angle glaucoma
- Severe GI conditions (toxic megacolon)
- Hemodialysis, severe hepatic impairment
- Strong CYP3A4 inhibitors with severe renal/moderate hepatic impairment
Drug interactions
- Anticholinergics: Increased therapeutic and undesirable effects
- Cholinergic receptor agonists: Reduced therapeutic effect
- Metoclopramide, cisapride: Reduced effect
- Strong CYP3A4 inhibitors (ketoconazole, ritonavir, itraconazole): 2-3 fold increase in solifenacin AUC (limit to 5 mg)
Food interactions
Caution is advised when consuming alcohol with Solifenacin Succinate; consult your doctor.
Use in pregnancy
Use in Pregnancy: May be unsafe; animal studies show harmful effects; use only if clearly needed; consult your doctor.
Pregnancy Category: C — always consult a doctor before taking during pregnancy.
Use in lactation
Use in Lactation: Safe during breastfeeding; limited data suggests no significant risk; long-term use may reduce milk production and cause constipation in infants; consult your doctor.
Pediatric use
Safety and efficacy not established in children; do not use
Geriatric use
Indicated for elderly (no dose adjustment needed)
Renal / hepatic impairment
Renal Impairment: Mild-moderate: no dose adjustment; severe (CrCl <30): max 5 mg/day; do not use in dialysis patients; consult your doctor.
Hepatic Impairment: Mild: no dose adjustment; moderate (Child-Pugh B): max 5 mg/day; severe: do not use; consult your doctor.
Overdose effects
Overdose may cause severe anticholinergic effects; highest dose 280 mg/5 hours caused mental status changes; activated charcoal; gastric lavage (within 1 hour); physostigmine, benzodiazepines, beta-blockers, catheterization; caution in QT-prolongation risk.
Storage conditions
Store in a cool and dry place, protected from light; keep out of reach of children.
Chemical structure
Solifenacin Succinate